Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

Bayer stresses drug's tolerability in bid for prostate cancer market

Reuters Thursday, 14 February 2019
Bayer is banking on the mild side effects of its experimental prostate cancer drug darolutamide, as it prepares to take on established rival products by Pfizer and Johnson & Johnson.
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related videos from verified sources

Bayer's dilemma [Video]Bayer's dilemma

► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs German healthcare group Bayer has made a €2bn bid for Norway's Algeta, hoping to gain full control over a potentially..

Credit: Financial Times     Duration: 03:04Published


Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.